Brii Bio antibody impactful against Omicron and other variants

28 July 2022

pandemic_covid_money_market_impact_large_shutterstock

China-based Brii Biosciences (HKG: 2137) has announced new live virus data confirming that the amubarvimab/romlusevimab combination, a long-acting COVID-19 monoclonal antibody therapy, retains neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.

The drug combination is already approved in China for the treatment of adults and pediatric patients with COVID-19 at high risk for progression to severe disease. In July 2022, the amubarvimab/romlusevimab combination was made commercially available in China.

Human pharmacokinetic data from the University of Maryland indicates that total serum concentrations of the combination will remain above the level required for neutralizing activity against the subvariants. As a result, adequate therapeutic exposures are expected to persist throughout the treatment period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK